

Biosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases), By End Use (Hospitals, Clinics, Homecare, Research Institutions), By Manufacturing Process (Recombinant DNA Technology, Hybridoma Technology, Transgenic Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2032

Market Report | 2025-02-14 | 215 pages | Market Research Future

AVAILABLE LICENSES:

- Single User Price \$4950.00
- Enterprisewide Price \$7250.00

Report description:

Biosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases), By End Use (Hospitals, Clinics, Homecare, Research Institutions), By Manufacturing Process (Recombinant DNA Technology, Hybridoma Technology, Transgenic Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2032

Market Overview

The biosimilars market is predicted to expand from 11.39 (USD Billion) in 2023 to 41.6 (USD Billion) by 2032. The Biosimilars Market CAGR (growth rate) is anticipated to be approximately 15.49% over the forecast period.

Several main drivers are driving the biosimilars industry, including an increase in the prevalence of chronic diseases and a growing need for inexpensive biologic treatments. As healthcare costs continue to grow, biosimilars provide a cost-effective alternative that can improve patient access to critical therapies. Regulatory reforms and developments in manufacturing processes also contribute to market growth by streamlining the approval process and improving product quality. The transition to value-based care models stresses the necessity of low-cost treatment choices, making biosimilars a crucial component of the healthcare ecosystem.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Market segment insights

The Biosimilars Market is expanding rapidly, notably in the Type category, which includes key medicinal goods such as monoclonal antibodies, insulin, erythropoietin, and growth hormones.

The Biosimilars Market is growing rapidly, with a valuation of 11.39 USD billion in 2023 and a forecast revenue of 41.6 USD billion by 2032. This expansion can be attributable to rising demand for more cost-effective treatment alternatives across a variety of therapeutic areas, particularly in the Application segment.

In the Biosimilars Market, the End Use segment is critical to establishing the landscape of healthcare delivery. By 2023, the total market is predicted to be worth 11.39 billion USD, indicating the industry's strong expansion. Hospitals are a prominent player in this area, as they increasingly use biosimilars to reduce treatment costs and improve patient outcomes. Clinics also make a substantial contribution, catering to a vast patient population seeking cost-effective solutions in a variety of therapeutic fields.

The Biosimilars sector was assessed at 11.39 USD billion in 2023, with strong growth projected in the following years as the sector transitions to advanced manufacturing technologies. Within the Manufacturing Process category, technologies such as Recombinant DNA Technology and Hybridoma Technology play critical roles in biosimilar development.

Regional insights

The Biosimilars Market is expected to grow rapidly across all regions, with North America, Europe, APAC, South America, and MEA contributing significantly to revenue. North America maintains a majority stake worth 5.0 USD billion in 2023 and is expected to grow to 17.5 USD billion by 2032, proving its dominance in the business due to a robust healthcare infrastructure and increased demand for cost-effective therapies. Europe follows closely, with a valuation of 3.5 USD billion in 2023 and a projected growth rate of 13.0 USD billion, owing to favorable regulations and increased acceptance of biosimilars among healthcare professionals.

The APAC region is rising, with a value of 2.0 USD billion in 2023 and an expected growth to 8.0 USD billion, demonstrating promise due to growing patient populations and increased healthcare investments. South America and MEA are smaller markets, with valuations of 0.7 USD billion and 0.19 USD billion respectively in 2023, but they offer chances for growth as healthcare systems expand and access to biosimilars improves. The overall Biosimilars Market data reflects a dynamic growth landscape influenced by regional healthcare policies, patient access to medications, and the economic benefits associated with biosimilar therapies.

Key players

Key Companies in the Biosimilars Market Include Zydus Cadila, Eli Lilly, Samsung Bioepis, GSK, AbbVie, Boehringer Ingelheim, Teva Pharmaceutical Industries, Celltrion, Fresenius Kabi, Amgen, Reddy's Laboratories, Mylan, Sandoz, Pfizer, and Novartis.

Table of Contents:

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

1.1. MARKET OVERVIEW

1.2. KEY FINDINGS

1.3. MARKET SEGMENTATION

1.4. COMPETITIVE LANDSCAPE

1.5. CHALLENGES AND OPPORTUNITIES

1.6. FUTURE OUTLOOK

2. MARKET INTRODUCTION

2.1. DEFINITION

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.2. SCOPE OF THE STUDY
 - 2.2.1. RESEARCH OBJECTIVE
 - 2.2.2. ASSUMPTION
 - 2.2.3. LIMITATIONS
- 3. RESEARCH METHODOLOGY
 - 3.1. OVERVIEW
 - 3.2. DATA MINING
 - 3.3. SECONDARY RESEARCH
 - 3.4. PRIMARY RESEARCH
 - 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
 - 3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS
 - 3.5. FORECASTING MODEL
 - 3.6. MARKET SIZE ESTIMATION
 - 3.6.1. BOTTOM-UP APPROACH
 - 3.6.2. TOP-DOWN APPROACH
 - 3.7. DATA TRIANGULATION
 - 3.8. VALIDATION
- 4. MARKET DYNAMICS
 - 4.1. OVERVIEW
 - 4.2. DRIVERS
 - 4.3. RESTRAINTS
 - 4.4. OPPORTUNITIES
- 5. MARKET FACTOR ANALYSIS
 - 5.1. VALUE CHAIN ANALYSIS
 - 5.2. PORTER'S FIVE FORCES ANALYSIS
 - 5.2.1. BARGAINING POWER OF SUPPLIERS
 - 5.2.2. BARGAINING POWER OF BUYERS
 - 5.2.3. THREAT OF NEW ENTRANTS
 - 5.2.4. THREAT OF SUBSTITUTES
 - 5.2.5. INTENSITY OF RIVALRY
 - 5.3. COVID-19 IMPACT ANALYSIS
 - 5.3.1. MARKET IMPACT ANALYSIS
 - 5.3.2. REGIONAL IMPACT
 - 5.3.3. OPPORTUNITY AND THREAT ANALYSIS
- 6. BIOSIMILARS MARKET, BY TYPE (USD BILLION)
 - 6.1. MONOCLONAL ANTIBODIES
 - 6.2. INSULIN
 - 6.3. ERYTHROPOIETIN
 - 6.4. GROWTH HORMONES
- 7. BIOSIMILARS MARKET, BY APPLICATION (USD BILLION)
 - 7.1. ONCOLOGY
 - 7.2. DIABETES
 - 7.3. AUTOIMMUNE DISEASES
 - 7.4. CHRONIC INFLAMMATORY DISEASES
- 8. BIOSIMILARS MARKET, BY END USE (USD BILLION)
 - 8.1. HOSPITALS
 - 8.2. CLINICS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3. HOMECARE
- 8.4. RESEARCH INSTITUTIONS
- 9. BIOSIMILARS MARKET, BY MANUFACTURING PROCESS (USD BILLION)
 - 9.1. RECOMBINANT DNA TECHNOLOGY
 - 9.2. HYBRIDOMA TECHNOLOGY
 - 9.3. TRANSGENIC TECHNOLOGY
- 10. BIOSIMILARS MARKET, BY REGIONAL (USD BILLION)
 - 10.1. NORTH AMERICA
 - 10.1.1. US
 - 10.1.2. CANADA
 - 10.2. EUROPE
 - 10.2.1. GERMANY
 - 10.2.2. UK
 - 10.2.3. FRANCE
 - 10.2.4. RUSSIA
 - 10.2.5. ITALY
 - 10.2.6. SPAIN
 - 10.2.7. REST OF EUROPE
 - 10.3. APAC
 - 10.3.1. CHINA
 - 10.3.2. INDIA
 - 10.3.3. JAPAN
 - 10.3.4. SOUTH KOREA
 - 10.3.5. MALAYSIA
 - 10.3.6. THAILAND
 - 10.3.7. INDONESIA
 - 10.3.8. REST OF APAC
 - 10.4. SOUTH AMERICA
 - 10.4.1. BRAZIL
 - 10.4.2. MEXICO
 - 10.4.3. ARGENTINA
 - 10.4.4. REST OF SOUTH AMERICA
 - 10.5. MEA
 - 10.5.1. GCC COUNTRIES
 - 10.5.2. SOUTH AFRICA
 - 10.5.3. REST OF MEA
- 11. COMPETITIVE LANDSCAPE
 - 11.1. OVERVIEW
 - 11.2. COMPETITIVE ANALYSIS
 - 11.3. MARKET SHARE ANALYSIS
 - 11.4. MAJOR GROWTH STRATEGY IN THE BIOSIMILARS MARKET
 - 11.5. COMPETITIVE BENCHMARKING
 - 11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE BIOSIMILARS MARKET
 - 11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
 - 11.7.1. NEW PRODUCT LAUNCH/SERVICE DEPLOYMENT
 - 11.7.2. MERGER & ACQUISITIONS
 - 11.7.3. JOINT VENTURES

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.8. MAJOR PLAYERS FINANCIAL MATRIX
 - 11.8.1. SALES AND OPERATING INCOME
 - 11.8.2. MAJOR PLAYERS R&D EXPENDITURE. 2023
- 12. COMPANY PROFILES
 - 12.1. ZYDUS CADILA
 - 12.1.1. FINANCIAL OVERVIEW
 - 12.1.2. PRODUCTS OFFERED
 - 12.1.3. KEY DEVELOPMENTS
 - 12.1.4. SWOT ANALYSIS
 - 12.1.5. KEY STRATEGIES
 - 12.2. ELI LILLY
 - 12.2.1. FINANCIAL OVERVIEW
 - 12.2.2. PRODUCTS OFFERED
 - 12.2.3. KEY DEVELOPMENTS
 - 12.2.4. SWOT ANALYSIS
 - 12.2.5. KEY STRATEGIES
 - 12.3. SAMSUNG BIOEPIS
 - 12.3.1. FINANCIAL OVERVIEW
 - 12.3.2. PRODUCTS OFFERED
 - 12.3.3. KEY DEVELOPMENTS
 - 12.3.4. SWOT ANALYSIS
 - 12.3.5. KEY STRATEGIES
 - 12.4. GSK
 - 12.4.1. FINANCIAL OVERVIEW
 - 12.4.2. PRODUCTS OFFERED
 - 12.4.3. KEY DEVELOPMENTS
 - 12.4.4. SWOT ANALYSIS
 - 12.4.5. KEY STRATEGIES
 - 12.5. ABBVIE
 - 12.5.1. FINANCIAL OVERVIEW
 - 12.5.2. PRODUCTS OFFERED
 - 12.5.3. KEY DEVELOPMENTS
 - 12.5.4. SWOT ANALYSIS
 - 12.5.5. KEY STRATEGIES
 - 12.6. BOEHRINGER INGELHEIM
 - 12.6.1. FINANCIAL OVERVIEW
 - 12.6.2. PRODUCTS OFFERED
 - 12.6.3. KEY DEVELOPMENTS
 - 12.6.4. SWOT ANALYSIS
 - 12.6.5. KEY STRATEGIES
 - 12.7. TEVA PHARMACEUTICAL INDUSTRIES
 - 12.7.1. FINANCIAL OVERVIEW
 - 12.7.2. PRODUCTS OFFERED
 - 12.7.3. KEY DEVELOPMENTS
 - 12.7.4. SWOT ANALYSIS
 - 12.7.5. KEY STRATEGIES
 - 12.8. CELLTRION

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.8.1. FINANCIAL OVERVIEW
- 12.8.2. PRODUCTS OFFERED
- 12.8.3. KEY DEVELOPMENTS
- 12.8.4. SWOT ANALYSIS
- 12.8.5. KEY STRATEGIES
- 12.9. FRESENIUS KABI
 - 12.9.1. FINANCIAL OVERVIEW
 - 12.9.2. PRODUCTS OFFERED
 - 12.9.3. KEY DEVELOPMENTS
 - 12.9.4. SWOT ANALYSIS
 - 12.9.5. KEY STRATEGIES
- 12.10. AMGEN
 - 12.10.1. FINANCIAL OVERVIEW
 - 12.10.2. PRODUCTS OFFERED
 - 12.10.3. KEY DEVELOPMENTS
 - 12.10.4. SWOT ANALYSIS
 - 12.10.5. KEY STRATEGIES
- 12.11. REDDY'S LABORATORIES
 - 12.11.1. FINANCIAL OVERVIEW
 - 12.11.2. PRODUCTS OFFERED
 - 12.11.3. KEY DEVELOPMENTS
 - 12.11.4. SWOT ANALYSIS
 - 12.11.5. KEY STRATEGIES
- 12.12. MYLAN
 - 12.12.1. FINANCIAL OVERVIEW
 - 12.12.2. PRODUCTS OFFERED
 - 12.12.3. KEY DEVELOPMENTS
 - 12.12.4. SWOT ANALYSIS
 - 12.12.5. KEY STRATEGIES
- 12.13. SANDOZ
 - 12.13.1. FINANCIAL OVERVIEW
 - 12.13.2. PRODUCTS OFFERED
 - 12.13.3. KEY DEVELOPMENTS
 - 12.13.4. SWOT ANALYSIS
 - 12.13.5. KEY STRATEGIES
- 12.14. PFIZER
 - 12.14.1. FINANCIAL OVERVIEW
 - 12.14.2. PRODUCTS OFFERED
 - 12.14.3. KEY DEVELOPMENTS
 - 12.14.4. SWOT ANALYSIS
 - 12.14.5. KEY STRATEGIES
- 12.15. NOVARTIS
 - 12.15.1. FINANCIAL OVERVIEW
 - 12.15.2. PRODUCTS OFFERED
 - 12.15.3. KEY DEVELOPMENTS
 - 12.15.4. SWOT ANALYSIS
 - 12.15.5. KEY STRATEGIES

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13. APPENDIX

13.1. REFERENCES

13.2. RELATED REPORTS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Biosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases), By End Use (Hospitals, Clinics, Homecare, Research Institutions), By Manufacturing Process (Recombinant DNA Technology, Hybridoma Technology, Transgenic Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2032

Market Report | 2025-02-14 | 215 pages | Market Research Future

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$4950.00
	Enterprisewide Price	\$7250.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-13"/>
		Signature	<input type="text"/>